
Seaport Therapeutics Publishes Science Translational Medicine Study on GlyphAllo™ (SPT-300) Prodrug
PureTech Founded Entity Seaport Therapeutics Publishes First-in-Human Data on GlyphAllo™ (SPT-300) in Science Translational Medicine PureTech Health plc a biotherapeutics company focused on advancing innovative science into impactful medicines, announced that its Founded Entity, Seaport Therapeutics, has published significant clinical…












